TREAT OA

Translational Research in Europe – Applied Technologies for Osteoarthritis

 Coordinatore KING'S COLLEGE LONDON 

 Organization address address: Strand
city: LONDON
postcode: WC2R 2LS

contact info
Titolo: Mr.
Nome: Paul
Cognome: Labbett
Email: send email
Telefono: +44 20 7848 8184
Fax: +44 20 7848 8187

 Nazionalità Coordinatore United Kingdom [UK]
 Sito del progetto http://www.treatoa.eu/
 Totale costo 16˙673˙604 €
 EC contributo 11˙924˙660 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-A
 Funding Scheme CP-IP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-01-01   -   2013-06-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    KING'S COLLEGE LONDON

 Organization address address: Strand
city: LONDON
postcode: WC2R 2LS

contact info
Titolo: Mr.
Nome: Paul
Cognome: Labbett
Email: send email
Telefono: +44 20 7848 8184
Fax: +44 20 7848 8187

UK (LONDON) coordinator 0.00
2    ACADEMISCH ZIEKENHUIS LEIDEN

 Organization address address: Albinusdreef 2
city: LEIDEN
postcode: 2333 ZA

contact info
Titolo: Ms.
Nome: Liesbeth
Cognome: Dorama
Email: send email
Telefono: +31 71 5269569
Fax: +31 71 5268275

NL (LEIDEN) participant 0.00
3    ARCARIOS

 Organization address address: AGORALAAN A BIS
city: DIEPENBEEK
postcode: 3590

contact info
Titolo: Mr.
Nome: Guido
Cognome: Maertens
Email: send email
Telefono: 3123951973

BE (DIEPENBEEK) participant 0.00
4    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

 Organization address address: 's Gravendijkwal 230
city: ROTTERDAM
postcode: 3015CE

contact info
Titolo: Mr.
Nome: Jan Willem
Cognome: Te Ronde
Email: send email
Telefono: 31107038425

NL (ROTTERDAM) participant 0.00
5    ISLENSK ERFDAGREINING EHF

 Organization address address: Sturlugata 8
city: REYKJAVIK
postcode: 101

contact info
Titolo: Mr.
Nome: Gudmundur
Cognome: Einarsson
Email: send email
Telefono: +354 570 1900
Fax: +354 570 1981

IS (REYKJAVIK) participant 0.00
6    KATHOLIEKE UNIVERSITEIT LEUVEN

 Organization address address: Oude Markt 13
city: LEUVEN
postcode: 3000

contact info
Titolo: Ms.
Nome: Maria
Cognome: Vereeken
Email: send email
Telefono: +32 16 32 65 04
Fax: +32 16 32 65 15

BE (LEUVEN) participant 0.00
7    KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW

 Organization address address: KLOVENIERSBURGWAL 29 HET TRIPPENHUIS
city: AMSTERDAM
postcode: 1011 JV

contact info
Titolo: Mr.
Nome: Don
Cognome: Van Velzen
Email: send email
Telefono: +31 30 21 21 863
Fax: +31 30 21 21 865

NL (AMSTERDAM) participant 0.00
8    SYNARC SAS

 Organization address address: RUE DE MONTBRILLANT 16
city: LYON
postcode: 69003

contact info
Titolo: Dr.
Nome: Patrick
Cognome: Garnero
Email: send email
Telefono: +33 472 68 65 05
Fax: +33 472 68 65 08

FR (LYON) participant 0.00
9    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

 Organization address address: University Offices, Wellington Square
city: OXFORD
postcode: OX1 2JD

contact info
Titolo: Mr.
Nome: Edward
Cognome: Gibbs
Email: send email
Telefono: +441865 857 212
Fax: +441865 857 213

UK (OXFORD) participant 0.00
10    TiGENIX NV

 Organization address address: RESEARCHPARK HAASRODE 1724 ROMEINSE STRAAT 12/2
city: LEUVEN
postcode: 3001

contact info
Titolo: Mr.
Nome: Luc
Cognome: Dochez
Email: send email
Telefono: +32 16 39 60 60
Fax: +32 16 39 60 50

BE (LEUVEN) participant 0.00
11    UNIVERSITY OF IOANNINA

 Organization address address: "LEOFOROS STAVROS S NIARCHOS, PANEPISTIMIOUPOLI IOANNINON"
city: IOANNINA
postcode: 45110

contact info
Titolo: Prof.
Nome: George
Cognome: Papageorgiou
Email: send email
Telefono: +30 26 51 09 72 87
Fax: +30 26 51 09 72 00

EL (IOANNINA) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

aetiology    clinical    treatment    modifying    pathways    risk    diagnostics    technologies    drugs    disease    oa    treat    progression    panel    diagnosis    biochemical    markers    genetic    genes   

 Obiettivo del progetto (Objective)

'TREAT-OA will address the need for better treatment and diagnostics for osteoarthritis (OA) - the most common cause of disability in Europe. Currently there are no drugs that can cure, reverse or halt the disease. Nor are there yet reliable clinical biochemical markers for diagnosis or prognosis which is an impediment to the management of OA, costs of therapeutic trials and the development of disease modifying drugs. TREAT-OA represents a large-scale collaborative, integrated, trans-disciplinary project utilising a resource of 28,000 OA phenotyped subjects with available genome-wide association scan data as well as leading basic science laboratories and technologies. This is the largest study of its kind that will address the generalisability and utility of genetic and biochemical risk factors throughout the EU. The key objectives of TREAT-OA are to: 1 Identify genes and biochemical markers consistently associated with risk and progression of OA 2 Use such genes to further our understanding of the molecular pathways involved in disease aetiology 3 Analyze pathways to identify targets for pharmacological intervention 4 Develop transgenic animal laboratory OA model systems . 5 Develop a panel of genetic and biochemical diagnostics for risk and progression of OA 6 Disseminate results from this extensive research at large and use results and technologies for training within the EU TREAT-OA will help develop European clinical and scientific excellence in the diagnosis and treatment of OA. The novel pathways in disease aetiology discovered will translate into novel drug targets and protein therapeutics for OA. The development of in vitro and in vivo assays will provide a comprehensive technology platform enabling the discovery and development of disease modifying drugs for OA. TREAT-OA will also make a major impact on the disease via a diagnostic panel of genes and biochemical markers for selecting severe cases and rapidly progressing individuals.'

Altri progetti dello stesso programma (FP7-HEALTH)

AUTOCAST (2008)

Automatic Cancer Screening Based on Real-time PCR

Read More  

CVGENES-AT-TARGET (2013)

Exploitation of genomic variants affecting coronary artery disease and stroke risk for therapeutic intervention

Read More  

CARTARDIS (2013)

Identification and validation of novel pharmaceutical drug targets for cardiovascular disease

Read More